<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844090</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-011-08F</org_study_id>
    <nct_id>NCT00844090</nct_id>
  </id_info>
  <brief_title>The Role of Apathy in Glycemic Control</brief_title>
  <official_title>The Role of Apathy in Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In spite of several new medications and insulins for the control of blood sugars in patients
      with diabetes, a large number of patients do not have good control. This likely due to
      inability to carry out regular activities and self-care behaviors such as taking meds
      regularly, keeping a good diet, exercise etc. This inability to carry out self care lifestyle
      changes may be due to a condition called apathy. Apathy is a lack of motivation and
      persistence. In this study we will attempt to treat apathy with a medication called
      methylphenidate for 6 months and see if blood sugar/diabetes control improves.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of diabetes in the US is at epidemic proportions. A large number of diabetes
      patients in the VA system have uncontrolled diabetes with high HbA1c. The inability to carry
      out important self-care behaviors such as measuring blood sugars regularly, following diet,
      exercise and medication programs may be due to apathy. Apathy is the lack of motivation,
      persistence and novelty. We have found this to be very prevalent in the VA diabetes
      population. We now do a randomized placebo controlled trial to see if treatment of apathy
      with methylphenidate will improve glycemic control in patients with A1c &gt;8. Treatment will be
      for 6 months. The primary end point is HbA1c.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c Over Baseline</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>measure of longer term glycemic control. A1c measured at baseline 6 weeks and 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Apathy</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylphenidate tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate or placebo</intervention_name>
    <description>treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor glycemic control HbA1c&gt;8

          -  Presence of apathy, a score of &gt;30 on AES

          -  Subjects should be on stable dose of metformin, thiozolidinediones, and sulfonylureas,
             statins and ACE inhibitors for at least two months

          -  Subjects should have a negative cardiac stress test within the previous year

        Exclusion Criteria:

          -  Presence of major depressive disorder, psychosis, suicidal ideations, and history of
             stimulant dependence as evaluated by MINI.

          -  Patient currently being treated or a history hypersensitivity to methylphenidate

          -  Hypertension with BP&gt;140/90

          -  History of renal disease with GFR&lt;60

          -  History of hepatic failure with AST/ALT &gt; three times the normal range

          -  History of seizure disorder, or Tourette's syndrome or presence of motor tics

          -  Patients with glaucoma

          -  Patients being treated with monoamine oxidase inhibitors (MAOIs) or Clonidine

          -  Patients with active cancer.

          -  Patients with acute illness needing hospitalization

          -  Patients with cardiovascular events such as myocardial infarction, stroke, amputation,
             unstable angina within the last six months.

          -  HbA1c&gt; 12

          -  Planned elective surgery in next 6 months

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrus DeSouza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Omaha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <results_first_submitted>December 2, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apathy</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Self-care behaviors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment period Oct 2009- Jan 2012.Participants recruited from Omaha VA outpatient clinics</recruitment_details>
      <pre_assignment_details>All participants underwent a stress echo after consent. If stress echo was positive patient was not assigned to randomized arms</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methylphenidate</title>
          <description>methylphenidate
methylphenidate 10mg twice daily P.O. : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
placebo only to treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants for analysis was 92 in total since only 92 participants completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Methylphenidate</title>
          <description>methylphenidate
methylphenidate : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
methylphenidate : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="9.9"/>
                    <measurement group_id="B2" value="56.0" spread="8.4"/>
                    <measurement group_id="B3" value="55.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c Over Baseline</title>
        <description>measure of longer term glycemic control. A1c measured at baseline 6 weeks and 6 months</description>
        <time_frame>6 months from baseline</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>methylphenidate
methylphenidate 10mg BID P.O. : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Placebo tabs BID P.O. : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Over Baseline</title>
          <description>measure of longer term glycemic control. A1c measured at baseline 6 weeks and 6 months</description>
          <population>per protocol</population>
          <units>percentage of HbA1c</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.02"/>
                    <measurement group_id="O2" value="-0.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Methyphenidate</title>
          <description>methylphenidate
methylphenidate 10mg bid p.o.: treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
Placebo bid p.o. : treat apathy to improve diabetes self care behaviors thereby improving glycemic control</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure and pulse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain, nausea, loose stool</sub_title>
                <description>adverse events only collected by organ system.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>hospitalization for cellulitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>nausea , bloating collected as GI organ system.</description>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="46"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <description>mild self limited</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cyrus Desouza MD</name_or_title>
      <organization>Omaha VA Medical Center</organization>
      <phone>402-995-5506</phone>
      <email>cyrus.desouza@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

